文献速递血液透析通路

HeRO移植物手术的围术期与长期结局

Perioperative and long-term outcomes after Hemodialysis Reliable Outflow (HeRO) graft surgery.
PubMed 文献 · J Vasc Surg · 2025-05-28

本单中心回顾性研究纳入2014至2023年三家医院的232例HeRO移植物植入,报告围术期并发症及通畅率,并分析 conduit 类型与构型对通畅率的影响。结果显示一期通畅率有限但二期通畅率可接受,锥形 conduit 与通畅率丧失独立相关。

要点

  • HeRO移植物一期通畅率1年33.0%±3.4%、3年6.4%±2.1%、5年4.3%±1.9%。
  • 二期通畅率1年69.4%±3.4%、3年41.9%±4.4%、5年28.0%±4.9%。
  • 锥形4-6mm与4-7mm conduit 较非锥形6mm移植物与一期通畅丧失独立相关。

核心结论

  • 在透析通路选择有限的患者中,HeRO移植物植入与有限的一期通畅率相关,但二期通畅率可接受。
  • 分期手术与早期穿刺移植物未影响通畅率,而使用锥形 conduit 与通畅率丧失相关,在该人群中应谨慎考虑。

研究设计与样本

  • 单中心回顾性研究,回顾2014年1月至2023年12月三家医院所有HeRO移植物手术,仅纳入首次HeRO植入,共232例。
  • 收集患者人口学、手术细节、术后结局与通畅率数据,采用Cox比例风险模型分析移植物通畅丧失的危险因素。

主要发现

  • 术后并发症包括伤口感染18例(7.8%)、症状性血肿23例(9.9%)、窃血综合征23例(9.9%)、心肌梗死3例(1.3%)、肺栓塞7例(3.0%)。
  • 一期与分期手术的一期通畅率(log-rank P = .46)和二期通畅率(log-rank P = .73)无显著差异。
  • 多因素分析中,与非锥形6mm移植物相比,锥形4-6mm conduit 与一期通畅丧失独立相关(HR 2.89;95%CI 1.11-7.49;P = .029),锥形4-7mm conduit 亦相关(HR 1.82;95%CI 1.15-2.87;P = .011)。
  • 锥形 conduit 亦与二期通畅丧失相关:4-6mm锥形(HR 3.68;95%CI 1.07-12.63;P = .039),4-7mm锥形(HR 1.85;95%CI 1.01-3.37;P = .044)。
  • 移植物类型(标准 vs 早期穿刺)或手术方式(首次 vs 分期)均与一期或二期通畅丧失无关。

关键数值与推荐

  • 共232例首次HeRO植入,其中首次手术49例(23.1%),分期手术183例(78.9%)。

临床怎么用

  • HeRO移植物可用于中心静脉狭窄或闭塞的透析患者,一期通畅率有限但二期通畅率可接受。
  • 在该患者人群中,使用锥形 conduit 与通畅率丧失相关,应谨慎考虑。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Hemodialysis Reliable Outflow (HeRO) graft offers hemodialysis access options for patients who have developed central venous stenosis or occlusion. In this single-center study, we report our perioperative and long-term outcomes after HeRO graft placement, and investigate the impact of conduit type and configuration on patency rates. METHODS: We retrospectively reviewed all HeRO graft procedures performed from January 2014 to December 2023 across three hospitals. Data were collected on patient demographics, operative details, postoperative outcomes, and patency. Only index HeRO graft procedures were included, and any subsequent or reoperative HeRO operations were excluded from analysis. Cox proportional hazards model was used to derive risk factors for loss of graft patency. RESULTS: A total of 232 index HeRO implantations were performed over the 10-year study period. These included 49 primary procedures (23.1%) and 183 staged procedures (78.9%). Postoperative complications included wound infection (n = 18; 7.8%), symptomatic hematoma (n = 23; 9.9%), steal syndrome (n = 23; 9.9%), myocardial infarction (n = 3; 1.3%), and pulmonary embolism (n = 7; 3.0%). Overall primary patency was 33.0% ± 3.4% at 1 year, 6.4% ± 2.1% at 3 years, and 4.3% ± 1.9% at 5 years post-implantation. Secondary patency was 69.4% ± 3.4% at 1 year, 41.9% ± 4.4% at 3 years, and 28.0% ± 4.9% at 5 years post-implantation. Primary and secondary patency rates did not differ between primary and staged procedures (log-rank P = .46 and .73, respectively). On multivariate analysis, the use of a tapered 4- to 6-mm (hazard ratio [HR], 2.89; 95% confidence interval [CI], 1.11-7.49; P = .029) or tapered 4- to 7-mm conduit (HR, 1.82; 95% CI, 1.15-2.87; P = .011) was independently associated with loss of primary patency, compared with a non-tapered 6-mm graft. Tapered conduits were also associated with loss of secondary patency (4- to 6-mm tapered: HR, 3.68; 95% CI, 1.07-12.63; P = .039; 4- to 7-mm tapered: HR, 1.85; 95% CI, 1.01-3.37; P = .044). Neither graft type (standard vs early cannulation) nor procedure (primary vs staged) were associated with loss of primary or secondary patency. CONCLUSIONS: Among patients with limited hemodialysis access options, HeRO graft implantation is associated with limited primary patency but acceptable secondary graft patency rates. In our experience, staged procedures and early cannulation grafts did not impact patency rates; however, the use of a tapered conduit was associated with loss of patency and should be considered with caution in this patient population.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kim Y, Cui CL, Eze AN, et al. Perioperative and long-term outcomes after Hemodialysis Reliable Outflow (HeRO) graft surgery. J Vasc Surg. 2025. PMID: 40447168. doi:10.1016/j.jvs.2025.05.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。